Recent advances in the discovery of zinc-binding motifs for the development of carbonic anhydrase inhibitors

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 30, Issue 2, 2015, Pages 321-324

  Winum, Jean Yves ^a   Supuran, Claudiu T ^b  

^a UNIVERSITÉ DE MONTPELLIER   (France)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Carbonic anhydrase; Inhibitors; Zinc binding motif

Indexed keywords

ALPHA CARBONATE DEHYDRATASE; AMINO ACID; ANTIGLAUCOMA AGENT; BETA CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE I; CARBONATE DEHYDRATASE II; CARBONATE DEHYDRATASE INHIBITOR; CARBONATE DEHYDRATASE IX; DITHIOCARBAMIC ACID DERIVATIVE; HYDROXAMIC ACID DERIVATIVE; PROTOZOAL PROTEIN; SALICYLALDOXIME; UNCLASSIFIED DRUG; XANTHIC ACID DERIVATIVE; ZINC ION; HYDROXAMIC ACID; OXIME; THIOCARBAMIC ACID DERIVATIVE; ZINC;

ANIMAL EXPERIMENT; ANIMAL MODEL; CANDIDA ALBICANS; CANDIDA GLABRATA; CRYPTOCOCCUS NEOFORMANS; CRYSTAL STRUCTURE; CYTOTOXICITY; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME INHIBITOR INTERACTION; GLAUCOMA; GROWTH INHIBITION; HYDROGEN BOND; HYDROPHILICITY; HYDROPHOBICITY; METAL BINDING; MOLECULAR DOCKING; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRYPANOSOMA; TRYPANOSOMA CRUZI; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DEVELOPMENT; PROCEDURES; SYNTHESIS; X RAY CRYSTALLOGRAPHY;

ANIMALIA; MAMMALIA; PROTOZOA; TRYPANOSOMA;

BINDING SITES; CARBONIC ANHYDRASE INHIBITORS; CARBONIC ANHYDRASES; CRYSTALLOGRAPHY, X-RAY; DRUG DISCOVERY; HYDROXAMIC ACIDS; MOLECULAR DOCKING SIMULATION; MOLECULAR STRUCTURE; OXIMES; THIOCARBAMATES; ZINC;

EID: 84926468993     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756366.2014.913587     Document Type: Review

References (22)

1. Supuran CT, Winum JY, eds. Drug design of zinc-enzyme inhibitors: Functional, structural, and disease applications. Hoboken (NJ): Wiley; 2009.
2. Supuran CT. Carbonic anhydrases: Novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008;7:168-81.
3. Supuran CT. Carbonic anhydrase inhibitors and activators for novel therapeutic applications. Future Med Chem 2011;3:1165-80.
4. Alterio V, Di Fiore A, D'Ambrosio K, et al. Multiple binding modes of inhibitors to carbonic anhydrases: How to design specific drugs targeting 15 different isoforms? Chem Rev 2012;112:4421-68.
5. Supuran CT. Structure-based drug discovery of carbonic anhydrase inhibitors. J Enzym Inhib Med Chem 2012;27:759-72.
6. Supuran CT. Carbonic anhydrase inhibition/activation: Trip of a scientist around the world in the search of novel chemotypes and drug targets. Curr Pharm Design 2010;16:3233-45.
7. Winum JY, Scozzafava A, Montero JL, Supuran CT. Design of zinc binding functions for carbonic anhydrase inhibitors. Curr Pharm Design 2008;14:615-21.
8. Winum JY, Scozzafava A, Montero JL, Supuran CT. Metal binding functions in the design of carbonic anhydrase inhibitors. Curr Top Med Chem 2007;7:835-48.
9. Winum JY, Scozzafava A, Montero JL, Supuran CT. New zinc binding motifs in the design of selective carbonic anhydrase inhibitors. Mini Rev Med Chem 2006;6:921-36.
10. Innocenti A, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Inhibition of transmembrane isoforms IX, XII, and XIV with less investigated anions including trithiocarbonate and dithiocarbamate. Bioorg Med Chem Lett 2010;20:1548-50.
11. Temperini C, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. X-ray crystal studies of the carbonic anhydrase IItrithiocarbonate adduct-an inhibitor mimicking the sulfonamide and urea binding to the enzyme. Bioorg Med Chem Lett 2010;20: 474-8.
12. Carta F, Aggarwal M, Maresca A, et al. Dithiocarbamates strongly inhibit carbonic anhydrases and show antiglaucoma action in vivo. J Med Chem 2012;55:1721-30.
13. Maresca A, Carta F, Vullo D, Supuran CT. Dithiocarbamates strongly inhibit the b-class carbonic anhydrases from Mycobacterium tuberculosis. J Enzyme Inhib Med Chem 2013; 28:407-11.
14. Monti SM, Maresca A, Viparelli F, et al. Dithiocarbamates are strong inhibitors of the beta-class fungal carbonic anhydrases from Cryptococcus neoformans, Candida albicans and Candida glabrata. Bioorg Med Chem Lett 2012;22:859-62.
15. Carta F, Aggarwal M, Maresca A, et al. Dithiocarbamates: A new class of carbonic anhydrase inhibitors. Crystallographic and kinetic investigations. Chem Comm 2012;48:1868-70.
16. Carta F, Akdemir A, Scozzafava A, et al. Xanthates and trithiocarbonates strongly inhibit carbonic anhydrases and show antiglaucoma effects in vivo. J Med Chem 2013;56:4691-700.
17. Scozzafava A, Supuran CT. Carbonic anhydrase and matrix metalloproteinase inhibitors: Sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes. J Med Chem 2000;43:3677-87.
18. Nuti E, Orlandini E, Nencetti S, et al. Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumorassociated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates. Bioorg Med Chem 2007;15: 2298-311.
19. Marques SM, Nuti E, Rossello E, et al. Dual inhibitors of matrix metalloproteinases and carbonic anhydrases: iminodiacetyl-based hydroxamate-benzenesulfonamide conjugates. J Med Chem 2008; 51:7968-79.
20. Di Fiore A, Maresca A, Supuran CT, De Simone G. Hydroxamate represents a versatile zinc binding group for the development of new carbonic anhydrase inhibitors. Chem Comm 2012;48:8838-40.
21. Rodrigues GC, Feijó DF, Bozza MT, et al. Design, synthesis, and evaluation of hydroxamic Acid derivatives as promising agents for the management of chagas disease. J Med Chem 2014;57: 298-308.
22. Tuccinardi T, Bertini S, Granchi C, et al. Salicylaldoxime derivatives as new leads for the development of carbonic anhydrase inhibitors. Bioorg Med Chem 2013;21:1511-15.